Immunoprecise Antibodies announced the opening of its 3,200 square foot antibody production laboratory at Vancouver Island Technology Park.
The addition of this new laboratory allows for increased capacity for hybridoma projects, includes architectural and engineering features that enhance workflow and cleanliness, houses new equipment to expand services, and allows for Vivarium expanded capacity for hybridoma projects.
"The opening of new laboratory facilities provides the infrastructure for the implementation of our strategic growth initiatives of increasing capacity and expansion of our core business,” Tom D'Orazio, CEO of ImmunoPrecise, said. “Perhaps more importantly for our shareholders, since increasing sales is tied to our capacity, the additional capacity of this world class facility allows us to handle more projects which we expect to drive revenues."
Antibodies are naturally occurring proteins capable of binding to specific target molecules, or antigens. They have been used very widely in research assays, diagnostics, purification and therapeutics.
The company employs an experienced group of R&D scientists, and over the last 25 years its investments in research have led to the creation of innovative and proprietary technologies and methods that significantly improve the speed and efficiency of monoclonal antibody production.